November 2, 2020 — Boston, MA & Singapore — AIM Biotech has appointed Jim McGorry as its Chief Executive Officer. Mr. McGorry was appointed to lead the expansion of AIM’s proprietary organ-on-a-chip business. AIM’s platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development using the AIM chip. Mr. McGorry is a career executive in the medical device and biotech industry, leading cardiac and oncology operations at Genzyme Corp, serving as senior executive at Champions Oncology and Baxter Healthcare and most recently as CEO of Biostage.
McGorry commented, “Our priorities for our next phase of growth include building our operational infrastructure for sales, marketing, our services business and establishing a U.S. office; and launching valuable new chip designs and applications while adding customers from the biopharmaceutical industry.”
AIM's organ-on-a-chip technology mimics complex organs to more quickly discover candidates for clinical trials and increase their likelihood of success. It sets itself apart from competing technologies by its easy-to-use and scalable chip configuration that requires no capital equipment. The chip is based on technology from the lab of Roger Kamm, Ph.D., the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at Massachusetts Institute of Technology. The first AIM chip was launched in 2015. It is commercially validated by more than 100 research labs, 10 biopharmaceutical customers and 30 peer-reviewed publications based on their work with the AIM chip.
“The AIM chip was designed for ease-of-use in building disease models generating biologically relevant data,” said Kamm. “Jim's commercial experience and network as a biotech veteran will greatly help us expand our products and services to biotech and pharma.”
"Jim brings a track record of growing biotech and life science businesses," said Kuan Chee Mun, executive director and cofounder of AIM. "Under his leadership, we look forward to rapidly expanding our customer base into new geographies and markets."
Mr. McGorry is a career executive in the biotech industry, helming cardiac and oncology operations at Genzyme Corp and serving in executive roles at Champions Oncology and Baxter Healthcare. Based in Boston, Massachusetts, McGorry most recently led biotech startup Biostage as CEO to its first successful application for an investigational new drug with the U.S. Food and Drug Administration. McGorry holds an MBA in general healthcare from the Duke University Fuqua School of Business, and Bachelor of Science & Engineering from the U.S. Military Academy at West Point, where he was president of his class.
About AIM
AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development. That means more informed decisions and less wasted time. Streamline your workflow. Rethink how you look at life sciences. It's time to add the human element.
